Antimalarial drug no better than standard coronavirus care: study

Medical staff at the IHU Mediterranee Infection Institute in Marseille, France show packets of chloroquine and  hydroxychloroqui
Medical staff at the IHU Mediterranee Infection Institute in Marseille, France show packets of chloroquine and hydroxychloroquine

Hydroxychloroquine, an antimalarial drug dubbed a “gift from God” by US President Donald Trump for its potential ability to fight the new coronavirus, was found to be no more effective than standard treatment in a small Chinese study.

The paper, which was published in the Journal of Zhejiang University on March 6, looked at 30 COVID-19 patients, half of whom received the medicine.

After seven days, 13 of the patients who were on the tested negative, compared to 14 people who weren’t on it.

One of the patients on it went on to develop , while the median time taken for the individuals to recover was similar in both groups.

The sample size is considered too small to be statistically significant.

But a similar number of patients were examined in a recent French study that found the same drug to be highly effective at fighting the infection, especially when taken in combination with the antibiotic azithromycin.

That triggered heightened global interest in hydroxychloroquine, and a related compound called chloroquine, which are synthetic forms of quinine and have for decades been used to treat malaria, as well as and lupus.

President Donald Trump last week announced his administration was working with to expand access to the medicines so that more doctors can prescribe them “off label”—meaning not for their original intended use.

Trump has said they could be a “gift from God” and a “game changer,” even as many scientists have cautioned against overhyping unproven medicines before large scale are carried out.

Such experiments are considered the gold standard in the field, last months or years and involve thousands of patients, often from around the world.

Patients are assigned at random to either receive the drug under investigation or a placebo, and the studies are “blinded” meaning the participants and their doctors are unaware which group they are in, to further reduce bias.

New York state, now the US epicenter of the pandemic with more than 30,000 cases and almost 200 deaths, began such a trial on Tuesday.

A man in Arizona, meanwhile, died this week after he ingested a non-medical form of chloroquine used to fight parasites in aquariums.

His wife, who also took the substance and was hospitalized, reported they had heard Trump talk about the benefits of the medicine and decided to try it.


US fast-tracking antimalarials to treat coronavirus


More information:
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) www.zjujournals.com/med/EN/10. … 1008-9292.2020.03.03

© 2020 AFP

Citation:
Antimalarial drug no better than standard coronavirus care: study (2020, March 25)
retrieved 26 March 2020
from https://medicalxpress.com/news/2020-03-antimalarial-drug-standard-coronavirus.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Source link

Check Also

WHO troubled by ‘near-exponential’ growth of pandemic

Credit: CC0 Public Domain The World Health Organization said Wednesday it was deeply concerned about …

120*600 120*600